$138,000 in China, Over $400,000 in the U.S.: Why Foreign Patients Fly to China for CAR-T Cancer Care

On August 16, 2026, 59-year-old Josh walked out of Jiahui International Hospital in Shanghai. Dr. Xuan Linli, his lead oncologist, handed him a Ping An Kou — a traditional Chinese peace pendant, a wish for a safe journey home. Hours later, he boarded an 11.5-hour flight back to Auckland, alone.

Just a few months earlier, he could not eat and was being kept alive by enteral nutrition. His doctors in New Zealand had told him his treatment had failed.

1. Why Josh Flew 9,000 Kilometers

In late 2025, Josh was diagnosed with advanced gastroduodenal adenocarcinoma. Chemotherapy combined with immunotherapy did not stop the disease. From his hospital bed, he did what many patients with no options left do: he searched the global frontier of cancer treatment.

What he found was a drug that, at that moment, existed only in China.

On June 22, 2026, China's National Medical Products Administration approved satricabtagene autoleucel, known as satri-cel (development code CT041): the world's first — and so far the only — CAR-T cell therapy approved for a solid tumor. It is indicated for Claudin18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma after at least two prior treatment lines. Until then, every approved CAR-T therapy targeted blood cancers such as leukemia and lymphoma, even though solid tumors account for more than 90% of all malignancies. Its pivotal study, published in The Lancet, reported an objective response rate of 41% versus 4% in the control group, and median overall survival of roughly 9 months versus about 4 months.

Another "China-first" drug is already following the same path: ivonescimab, a bispecific antibody for lung cancer, had its U.S. marketing application accepted by the FDA in January 2026, with a review target date in November — months after patients could already receive it as a routine prescription in China.

Josh flew roughly 9,000 kilometers to Shanghai, and the process moved faster than he expected. Under the hospital's remote guidance, he first had his Claudin18.2 biomarker tested in New Zealand; only after it came back positive did he book the trip. His T cells were collected on July 6, then manufactured into his personalized CAR-T treatment, infused, and monitored in hospital. He was discharged on August 16 — about six weeks in total — becoming the world's first international patient to receive solid-tumor CAR-T therapy in China. Fifty-five treatment centers had been certified before the therapy's launch; according to an August 2026 CCTV report, the number of hospitals registered to use it had since grown to 64.

The price for one infusion: RMB 990,000, or about US$138,000. The same bill in the United States looks very different. U.S. CAR-T list prices run roughly US$462,000 to $594,000, and when hospitalization, monitoring and complication management are included, average total costs land between about $500,000 and $610,000, with around 8.5% of complex cases exceeding $1 million. In a written reply to Caixin magazine, Jiahui put it plainly: blood-cancer CAR-T in China costs about one-third of the U.S. price.

China's surgical edge comes from scale as well. A vice president of Peking University International Hospital told Caixin that Chinese thoracic surgeons typically perform 400 to 1,000 operations a year, compared with roughly 100 for their counterparts abroad.

Josh is far from alone. China's National Health Commission reports that key international-service hospitals recorded 1.28 million international patient visits in 2025, up 73.6% over three years, with patients from North America and Europe doubling. Cross-border medical service revenue exceeded RMB 80 billion in the first three quarters of 2025, growing at more than 30% a year, according to Caixin. In March 2026, nine Chinese ministries jointly issued a policy explicitly calling for building an "international medical tourism brand."

So what actually happens when a patient decides to go? The rest of this guide walks through the journey in order — before landing, during treatment, and after discharge.

2. Before You Land: Care That Starts Before the Flight

Many patients assume cross-border care begins at the airport. In practice, it begins at the booking stage.

According to Caixin, hospital international departments start collecting medical records and understanding symptoms during the appointment process, with dedicated hotlines and service platforms for overseas bookings. At Jiahui International Cancer Center, patients typically have a video consultation before arrival, meeting a team that includes an oncologist, a clinical pharmacist and a case manager; the treatment plan, logistics and precautions are all reviewed on the call. Josh's biomarker test was arranged remotely this way, from New Zealand — so no one flew across the world on a guess.

This kind of support is becoming systematized. In April 2026, Guangzhou launched an International Medical Tourism Service Center linking 17 pilot hospitals, offering overseas patients visa assistance, remote pre-consultation, multilingual translation, transport and accommodation arrangements, and post-operative follow-up. Shanghai pairs its tourism-pilot hospitals with transit visa-exemption policies for short medical visits. Visa invitation letters, expected appointment timelines and accommodation can all be arranged in advance through a hospital's international office or a licensed coordinator.

Before departure, patients themselves need to lock in three things: a completed records pre-review with a clear written acceptance from the Chinese hospital; confirmation of eligibility, including any required biomarker tests; and a settled budget and insurance plan. The detailed checklist is in Section 6.

3. During Treatment: Language, Speed, and a Safety Net

Language. Jiahui provides services in 8 languages and can issue medical records and certificates in more than 20, according to Caixin; English-speaking escorts and guides are now standard at major international-service hospitals. Josh's lead physician, Dr. Xuan Linli, Chief of Medical Oncology at Jiahui International Cancer Center, has nearly two decades of medical experience in the United States and is board-certified by the American Board of Internal Medicine in internal medicine, medical oncology and hematology. Josh later said the team's responsiveness and the ease of communication were key reasons he chose Shanghai over options he had explored in Saudi Arabia and the United States.

Speed. Dr. Xuan describes a detail that consistently surprises foreign patients: a full hematology and oncology workup — bone marrow biopsy, laboratory tests, PET-CT, echocardiogram, pulmonary function — is completed, with reports delivered and discussed with the patient, within 48 hours. In the United States, a PET-CT alone typically takes 3 to 7 days to schedule and often requires prior insurer authorization. Across the Chinese system, the average time from first cancer consultation to surgery is 1 to 2 weeks; in Western countries it is commonly measured in months. For patients with advanced cancer, waiting is itself a risk.

A safety net for new therapies. A novel drug is not "infuse and done." Caixin reported the case of an American patient treated in Shanghai with a China-approved immunotherapy drug who developed severe immune-related adverse events and was admitted to the ICU; the hospital convened multiple rounds of multidisciplinary consultations, including with the drug's principal investigator. When choosing a hospital, patients should verify three things beyond drug access: a functioning multidisciplinary tumor board, ICU and complication-management capability, and documented experience with the specific new therapy.

Daily life. Jiahui's team asks about dietary preferences, cultural customs and religious needs before patients arrive, and individualizes arrangements on the ward. When family cannot accompany the patient, staff provide regular updates to relatives abroad. Supportive care extends to the details of recovery — Josh's care even included acupuncture alongside his cancer treatment, and by discharge the ascites that had once required daily drainage had resolved.

4. The Bill: Out-of-Pocket Costs, Insurance, and How Pricing Works

Money deserves to be discussed early and precisely.

Patients who travel to China specifically for treatment mostly pay out of pocket, according to Caixin: fewer than 30% of international insurance providers can currently settle claims directly in China, so most patients pay upfront and claim reimbursement after returning home. International departments and VIP clinics at public hospitals sit outside the public insurance system and set their own prices, typically at 3 to 10 times public-insurance rates — around 8 to 10 times for procedure-based services such as surgery, and 2 to 5 times for lab tests and imaging. Seeing the same specialist costs RMB 50–100 in a regular clinic versus roughly RMB 200–600 at an international department; the international division of Beijing Children's Hospital lists registration fees of RMB 1,000–1,500.

Direct billing is expanding. Peking University International Hospital's international center already cooperates with 45 commercial insurance companies and is piloting a model in which a domestic insurer acts as an intermediary with international insurers, with the arrangement expected to launch within the year.

The practical advice for patients: before departure, ask your home insurer three questions — which costs at a Chinese hospital are reimbursable, what document formats and records are required, and whether pre-authorization is needed. Keep every payment receipt and English-language medical record.

Also note what the headline price excludes. The RMB 990,000 for satri-cel covers cell manufacturing and infusion only; conditioning chemotherapy, inpatient monitoring, diagnostics, and food and accommodation in China are billed separately. Plan a full self-pay budget, with a contingency for complication management.

5. Going Home: Handover, Follow-Up, and Medication

The end of treatment is not the end of the service.

Before Josh left Shanghai, Dr. Xuan held a direct physician-to-physician discussion with his attending doctor in New Zealand, reviewing his clinical course and coordinating the next stage of care; Jiahui also remains involved in his follow-up. This cross-border handover is the most critical link in the treatment loop — if the doctors back home cannot pick up the thread, treatment breaks.

Before discharge, patients should confirm four things: the schedule of post-treatment check-ups and a follow-up contact channel; how their home doctor will receive the handover; the rules for taking medication across borders (customs rules differ for prescription drugs and injectables — check in advance and carry an English-language prescription); and whom to contact in an emergency. Reputable hospitals provide an English discharge summary, a medication list and follow-up contacts; the complete records should be passed to the home doctor promptly after return.

6. Six Things to Do Before You Book Your Flight

1. Confirm eligibility before booking flights. CAR-T and similar therapies have strict biomarker and fitness requirements. Get tested, complete the records pre-review, and obtain a clear written acceptance from the Chinese hospital before traveling.

2. Budget for full self-pay. Beyond the drug itself, plan for hospitalization, complication management and living costs for any accompanying family. Total spending can run well above the headline price.

3. Verify insurance rules in advance. Reimbursable items, required document formats, and pre-authorization requirements — confirm each with your home insurer, and retain all receipts and English records.

4. Set realistic expectations. These are breakthrough therapies that extend survival and control disease, not guarantees of cure. In satri-cel's pivotal study, median overall survival was about 9 months — what these treatments buy is time and a chance.

5. Plan follow-up before you leave. Confirm the check-up schedule, obtain a translated discharge summary, and arrange the handover to your doctor at home.

6. Use legitimate channels. Work with hospitals or coordinators that have formal institutional partnerships, and be wary of individual brokers on social media whose credentials cannot be verified.

The Bottom Line

Thirty years ago, the medical-travel flow ran from China to the West. Today it runs both ways, driven by drugs approved in China first, costs around one-third of Western levels, diagnostics measured in days rather than weeks, and a service system being redesigned around international patients.

For patients overseas, China is becoming not just "the cheaper option" but "the option that exists nowhere else" — which is precisely why every link of the journey, from records review to discharge handover, deserves real preparation rather than crossed fingers.

Professional cross-border medical coordination services can help international patients with hospital appointments, medical records and translation, in-hospital accompaniment in China, and the handover of payment and insurance processes — making the journey across borders a more certain one.